Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy

被引:75
作者
Konstam, MA
Patten, RD
Thomas, I
Ramahi, T
La Bresh, K
Goldman, S
Lewis, W
Gradman, A
Self, KS
Bittner, V
Rand, W
Kinan, D
Smith, RJ
Ford, T
Segal, R
Udelson, JE
机构
[1] Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA
[2] Inst Med Res, Slidell, LA USA
[3] Brown Univ, Pawtucket, RI USA
[4] Vet Adm Hosp, Tucson, AZ USA
[5] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[6] Western Penn Hosp, Pittsburgh, PA 15224 USA
[7] Self Ctr PC, Fairhope, AL USA
[8] Univ Alabama Birmingham, Birmingham, AL USA
[9] Merck & Co Inc, West Point, PA USA
关键词
D O I
10.1067/mhj.2000.105302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The mechanism by which angiotensin-converting enzyme inhibitors reduce mortality rater and disease progression in patients with heart failure is likely mediated in part through prevention of adverse ventricular remodeling. This study examined the effects of the angiotensin-converting enzyme inhibitor captopril and the angiotensin II type 1 receptor antagonist losartan on ventricular volumes and function in elderly patients with heart failure and reduced left ventricular ejection fraction (less than or equal to 40%). Methods Patients underwent radionuclide ventriculograms (RVG) at baseline and were randomized to either captopril (n = 16) or losartan (n = 13). After 48 weeks, another RVG was obtained. Therapy was then withdrawn for at least 5 days, and the RVG was repeated while the patient was not receiving the drug. Results At 48 weeks both captopril and losartan significantly reduced left ventricular (LV) end-diastolic volume index (135 +/- 26 to 128 +/- 23 mL/m(2) for losartan, P < .05 vs baseline; 142 +/- 25 to 131 +/- 20 ml/m(2) for captopril, P < .01; mean (SD). Captopril also reduced LV end-systolic volume index (98 +/- 24 to 89 +/- 21 mL/m(2), P < .01 vs, baseline), whereas a nonsignificant trend was observed for the losartan group (97 +/- 23 to 90 +/- 16 mL/m(2), P = not significant). The betweengroup differences in the changes in LV volumes were not statistically significant. After drug withdrawal, LV end-diastolic volume index remained significantly lower than baseline in the captopril group (P < .01). Conclusions Both captopril and losartan prevent LV dilation, representing adverse ventricular remodeling, previously seen with placebo treatment. Reverse remodeling was observed in the captopril group. On the basis of these results, the relative effects on IV remodeling do not provide a rationale for a survival benefit of losartan over captopril.
引用
收藏
页码:1081 / 1087
页数:7
相关论文
共 40 条
[1]   STRUCTURAL BASIS OF END-STAGE FAILURE IN ISCHEMIC CARDIOMYOPATHY IN HUMANS [J].
BELTRAMI, CA ;
FINATO, N ;
ROCCO, M ;
FERUGLIO, GA ;
PURICELLI, C ;
CIGOLA, E ;
QUAINI, F ;
SONNENBLICK, EH ;
OLIVETTI, G ;
ANVERSA, P .
CIRCULATION, 1994, 89 (01) :151-163
[2]   MOLECULAR SIGNALING MECHANISMS CONTROLLING GROWTH AND FUNCTION OF CARDIAC FIBROBLASTS [J].
BOOZ, GW ;
BAKER, KM .
CARDIOVASCULAR RESEARCH, 1995, 30 (04) :537-543
[3]  
CALLAHAN RJ, 1982, J NUCL MED, V23, P315
[4]  
DEVITA C, 1994, LANCET, V343, P1115
[5]   COMPARISON OF THE EFFECTS OF LOSARTAN AND ENALAPRIL ON CLINICAL STATUS AND EXERCISE PERFORMANCE IN PATIENTS WITH MODERATE OR SEVERE CHRONIC HEART-FAILURE [J].
DICKSTEIN, K ;
CHANG, P ;
WILLENHEIMER, R ;
HAUNSO, S ;
REMES, J ;
HALL, C ;
KJEKSHUS, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (02) :438-445
[6]   Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease [J].
Doughty, RN ;
Whalley, GA ;
Gamble, G ;
MacMahon, S ;
Sharpe, N ;
Krum, H ;
Murray, Y ;
Tonkin, A ;
Trotter, A ;
Burton, R ;
Garrett, J ;
Lane, G ;
Watts, J ;
Geddes, C ;
Hall, C ;
Stephensen, J ;
Woodhouse, S ;
Davidson, T ;
Bradbury, J ;
Hamer, A ;
Hopkins, L ;
Jackson, D ;
Cross, D ;
Moreland, F ;
Hawtin, B ;
Kimber, V ;
Saunders, M ;
Thomson, A ;
Colquhoun, D ;
Goldsmith, J ;
Hicks, B ;
Bond, C ;
Flett, S ;
Murphy, J ;
Bruning, J ;
Jellyman, T ;
Nairn, L ;
Bartram, H ;
McCulloch, A ;
Milne, A ;
Prasad, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (05) :1060-1066
[7]   SELECTIVE GENE-EXPRESSION IN FAILING HUMAN HEART - QUANTIFICATION OF STEADY-STATE LEVELS OF MESSENGER-RNA IN ENDOMYOCARDIAL BIOPSIES USING THE POLYMERASE CHAIN-REACTION [J].
FELDMAN, AM ;
RAY, PE ;
SILAN, CM ;
MERCER, JA ;
MINOBE, W ;
BRISTOW, MR .
CIRCULATION, 1991, 83 (06) :1866-1872
[8]   HEMODYNAMIC AND NEUROHORMONAL EFFECTS OF THE ANGIOTENSIN-II ANTAGONIST LOSARTAN IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].
GOTTLIEB, SS ;
DICKSTEIN, K ;
FLECK, E ;
KOSTIS, J ;
LEVINE, TB ;
LEJEMTEL, T ;
DEKOCK, M .
CIRCULATION, 1993, 88 (04) :1602-1609
[9]   Comparison of changes in respiratory function and exercise oxygen uptake with Losartan versus Enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy [J].
Guazzi, M ;
Melzi, G ;
Agostoni, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (12) :1572-1576
[10]  
HOLMAN BL, 1979, J NUCL MED, V20, P1237